Bank OZK (OZK)

CTI BioPharma Stock Forecast

Stock Price Forecast

The 9 analysts that cover CTI BioPharma stock have a consensus rating of "Hold" and an average price target of $51.44, which forecasts a 7.57% increase in the stock price over the next year. The lowest target is $40 and the highest is $63.

Price Target: $51.44 (+7.57%)

Analyst Consensus: Hold

Target	Low	Average	Median	High
Price	$40	$51.44	$51	$63
Change	-16.35%	+7.57%	+6.65%	+31.74%

Analyst Ratings

The average analyst rating for CTI BioPharma stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.

Recommendation Trends

Rating	Feb '25	Mar '25	Apr '25	May '25	Jun '25	Jul '25
Strong Buy	1	1	0	0	0	0
Buy	1	1	1	1	1	2
Hold	7	7	7	7	7	8
Sell	0	0	0	0	0	0
Strong Sell	1	1	1	1	1	0
Total	10	10	9	9	9	10

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Timur Braziler Wells Fargo	Wells Fargo	Hold Maintains $48 → $49	Hold	Maintains	$48 → $49	+2.47%	Jul 21, 2025
Timur Braziler Wells Fargo	Wells Fargo	Hold Maintains $40 → $48	Hold	Maintains	$40 → $48	+0.38%	Jul 10, 2025
Daniel Tamayo Raymond James	Raymond James	Hold → Buy Upgrades $58	Hold → Buy	Upgrades	$58	+21.29%	Jul 8, 2025
Catherine Mealor Keefe, Bruyette & Woods	Keefe, Bruyette & Woods	Hold Maintains $50 → $48	Hold	Maintains	$50 → $48	+0.38%	Apr 22, 2025
Matt Olney Stephens & Co.	Stephens & Co.	Hold Maintains $59 → $54	Hold	Maintains	$59 → $54	+12.92%	Apr 21, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

1.75B

Increased by 17.94%

from 1.48B

Revenue Next Year

1.83B

Increased by 4.52%

from 1.75B

EPS This Year

6.16

Increased by 0.25%

from 6.14

EPS Next Year

6.56

Increased by 6.58%

from 6.16

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027
Revenue	780.71M	1.17B	1.15B	1.37B	1.48B	1.75B	1.83B	1.96B
Revenue Growth	-18.61%	49.36%	-1.20%	18.55%	8.45%	17.94%	4.52%	7.06%
EPS	2.26	4.47	4.54	5.87	6.14	6.16	6.56	6.80
EPS Growth	-31.60%	98.03%	1.57%	29.30%	4.60%	0.25%	6.58%	3.62%
Forward PE	-	-	-	-	-	7.77	7.29	7.03
No. Analysts	-	-	-	-	-	10	10	5

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	1.8B	2.0B	2.1B
Avg	1.7B	1.8B	2.0B
Low	1.7B	1.7B	1.8B

Revenue Growth

Revenue Growth	2025	2026	2027
High	24.1%	11.8%	14.3%
Avg	17.9%	4.5%	7.1%
Low	12.7%	-0.3%	1.2%

EPS Forecast

EPS	2025	2026	2027
High	6.65	7.34	7.61
Avg	6.16	6.56	6.80
Low	5.61	6.01	6.15

EPS Growth

EPS Growth	2025	2026	2027
High	8.2%	19.2%	16.0%
Avg	0.3%	6.6%	3.6%
Low	-8.6%	-2.4%	-6.3%

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.